Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS Trial

Victor J Del Brutto, Han-Christoph Diener, J Donald Easton, Christopher B Granger, Lisa Cronin, Eva Kleine, Claudia Grauer, Martina Brueckmann, Kazunori Toyoda, Peter D Schellinger, Philippe Lyrer, Carlos A Molina, Aurauma Chutinet, Christopher F Bladin, Conrado J Estol, Ralph L Sacco, Victor J Del Brutto, Han-Christoph Diener, J Donald Easton, Christopher B Granger, Lisa Cronin, Eva Kleine, Claudia Grauer, Martina Brueckmann, Kazunori Toyoda, Peter D Schellinger, Philippe Lyrer, Carlos A Molina, Aurauma Chutinet, Christopher F Bladin, Conrado J Estol, Ralph L Sacco

Abstract

Background We sought to determine recurrent stroke predictors among patients with embolic strokes of undetermined source (ESUS). Methods and Results We applied Cox proportional hazards models to identify clinical features associated with recurrent stroke among participants enrolled in RE-SPECT ESUS (Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients With Embolic Stroke of Undetermined Source) trial, an international clinical trial evaluating dabigatran versus aspirin for patients with ESUS. During a median follow-up of 19 months, 384 of 5390 participants had recurrent stroke (annual rate, 4.5%). Multivariable models revealed that stroke or transient ischemic attack before the index event (hazard ratio [HR], 2.27 [95% CI, 1.83-2.82]), creatinine clearance <50 mL/min (HR, 1.69 [95% CI, 1.23-2.32]), male sex (HR, 1.60 [95% CI, 1.27-2.02]), and CHA2DS2-VASc ≥4 (HR, 1.55 [95% CI, 1.15-2.08] and HR, 1.66 [95% CI, 1.21-2.26] for scores of 4 and ≥5, respectively) versus CHA2DS2-VASc of 2 to 3, were independent predictors for recurrent stroke. Conclusions In RE-SPECT ESUS trial, expected risk factors previously linked to other common stroke causes were associated with stroke recurrence. These data help define high-risk groups for subsequent stroke that may be useful for clinicians and for researchers designing trials among patients with ESUS. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02239120.

Keywords: embolic stroke of undetermined source; risk factors; secondary prevention; stroke predictors.

Figures

Figure 1. Factor importance of multivariable regression…
Figure 1. Factor importance of multivariable regression analysis of clinical predictors for recurrent stroke.
Selection of variables by Akaike criterion.

References

    1. Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke. 2017;48:867–872. doi: 10.1161/STROKEAHA.116.016414
    1. Diener H‐C, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, Kreuzer J, Cronin L, Cotton D, Grauer C, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380:1906–1917. doi: 10.1056/NEJMoa1813959
    1. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Wang Y, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378:2191–2201. doi: 10.1056/NEJMoa1802686
    1. Diener HC, Easton JD, Granger CB, Cronin L, Duffy C, Cotton D, Brueckmann M, Sacco RL. Design of Randomized, double‐blind, Evaluation in secondary Stroke Prevention comparing the Efficacy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE‐SPECT ESUS). Int J Stroke. 2015;10:1309–1312. doi: 10.1111/ijs.12630
    1. Hart RG, Veltkamp RC, Sheridan P, Sharma M, Kasner SE, Bangdiwala SI, Ntaios G, Shoamanesh A, Ameriso SF, Toni D, et al. Predictors of recurrent ischemic stroke in patients with embolic strokes of undetermined source and effects of rivaroxaban versus aspirin according to risk status: the NAVIGATE ESUS trial. J Stroke Cerebrovasc Dis. 2019;28:2273–2279. doi: 10.1016/j.jstrokecerebrovasdis.2019.05.014
    1. Koene RJ, Alraies MC, Norby FL, Soliman EZ, Maheshwari A, Lip GYH, Alonso A, Chen LY. Relation of the CHA2DS2‐VASc score to risk of thrombotic and embolic stroke in community‐dwelling individuals without atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] Study). Am J Cardiol. 2019;123:402–408. doi: 10.1016/j.amjcard.2018.10.037
    1. Víctor CU, Carolina PE, Jorge TR, Joaquín CR, Manuel SG, Marta CM, José María FV, Chinh PT, Javier OM, Susana MS, et al. Incidence and predictive factors of hidden atrial fibrillation detected by implantable loop recorder after an embolic stroke of undetermined source. J Atr Fibrillation. 2018;11:2078. doi: 10.4022/jafib.2078
    1. Ueno Y, Tateishi Y, Doijiri R, Kuriki A, Shimizu T, Kikuno M, Shimada Y, Takekawa H, Yamaguchi E, Koga M, et al. Large aortic arch plaques correlate with CHADS2 and CHA2DS2‐VASc scores in cryptogenic stroke. Atherosclerosis. 2019;284:181–186. doi: 10.1016/j.atherosclerosis.2019.03.009
    1. Ntaios G, Vemmos K, Lip GYH, Koroboki E, Manios E, Vemmou A, Rodríguez‐Campello A, Cuadrado‐Godia E, Giralt‐Steinhauer E, Arnao V, et al. Risk stratification for recurrence and mortality in embolic stroke of undetermined source. Stroke. 2016;47:2278–2285. doi: 10.1161/STROKEAHA.116.013713
    1. Ntaios G, Lip GYH, Lambrou D, Michel P, Perlepe K, Eskandari A, Nannoni S, Sirimarco G, Strambo D, Vemmos K, et al. Renal function and risk stratification of patients with embolic stroke of undetermined source. Stroke. 2018;49:2904–2909. doi: 10.1161/STROKEAHA.118.023281
    1. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524–1538. doi: 10.1046/j.1523-1755.2002.00600.x
    1. Verma N, Ziegler PD, Liu S, Passman RS. Incidence of atrial fibrillation among patients with an embolic stroke of undetermined source: insights from insertable cardiac monitors. Int J Stroke. 2019;14:146–153. doi: 10.1177/1747493018798554
    1. Bernstein RA, Kamel H, Granger CB, Piccini JP, Sethi PP, Katz JM, Vives CA, Ziegler PD, Franco NC, Schwamm LH, et al. Effect of long‐term continuous cardiac monitoring vs usual care on detection of atrial fibrillation in patients with stroke attributed to large‐ or small‐vessel disease: the STROKE‐AF randomized clinical trial. JAMA. 2021;325:2169–2177. doi: 10.1001/jama.2021.6470
    1. Strambo D, Sirimarco G, Nannoni S, Perlepe K, Ntaios G, Vemmos K, Michel P. Embolic stroke of undetermined source and patent foramen ovale: risk of paradoxical embolism score validation and atrial fibrillation prediction. Stroke. 2021;52:1643–1652. doi: 10.1161/STROKEAHA.120.032453
    1. Ntaios G, Georgiopoulos G, Perlepe K, Sirimarco G, Strambo D, Eskandari A, Nannoni S, Vemmou A, Koroboki E, Manios E, et al. A tool to identify patients with embolic stroke of undetermined source at high recurrence risk. Neurology. 2019;93:e2094–e2104. doi: 10.1212/WNL.0000000000008571
    1. Koutroulou I, Tsivgoulis G, Tsalikakis D, Karacostas D, Grigoriadis N, Karapanayiotides T. Epidemiology of patent foramen ovale in general population and in stroke patients: a narrative review. Front Neurol. 2020;11:281. doi: 10.3389/fneur.2020.00281

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel